INVA

Innoviva screens cheap — 7.0x P/E, 4.2x P/S, a fortress balance sheet ($551M cash vs. $258M long-term convertible notes, so net cash of ~$293M; current assets $728M against just $49.7M current liabilities), and 23.1% ROE. But the headline numbers flatter the business. The $271M FY2025 net income (+1,059% YoY, $3.30 diluted EPS) sits well above the $164M of operating income, meaning roughly $107M came from non-operating, mark-to-market gains on strategic stakes (Armata and other healthcare interests). Operating income actually fell 1.9%, so the 'earnings explosion' is lumpy investment income that will not recur on a straight line. Strip it out and normalized operating EPS is closer to ~$1.75, which makes the true multiple far less of a bargain.

The quality problem is deeper in the revenue mix. The MD&A shows the crown-jewel GSK royalties — the highest-margin, lowest-cost revenue — are declining: full-year gross royalty revenue was $250.3M vs. $255.6M in 2024, and Q4 royalties fell to $58.4M from $66.0M. All of 2025's 15% top-line growth came from net product sales ($172.1M, +77%), i.e., the hospital critical-care/anti-infective platform (GIAPREZA, XACDURO, XERAVA, ZEVTERA, NUZOLVENCE). That is a genuine transformation, but antibiotics carry notoriously poor commercial economics (reimbursement pressure, slow uptake) and are far lower-margin than royalties — the company is trading a melting high-margin annuity for a faster-growing but harder-to-monetize product book.